Advertisement

Topics

Sandoz’s rosuvastatin approved under China’s new Quality Consistency Evaluation system

06:24 EDT 14 Jun 2019 | Generics and Biosimilars Initiative

Sandoz, the generics division of Novartis, announced on 9 May 2019 that it had received regulatory approval from China's National Medical Products Administration (NMPA) for its generic rosuvastatin, under the recently introduced Quality Consistency Evaluation (QCE) system.

Original Article: Sandoz’s rosuvastatin approved under China’s new Quality Consistency Evaluation system

NEXT ARTICLE

More From BioPortfolio on "Sandoz’s rosuvastatin approved under China’s new Quality Consistency Evaluation system"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Generics Drugs
A generic drug (generic drugs, short: generics) is a drug defined as "a drug product that is comparable to brand/reference listed drug product in dosage form, strength, route of administration, quality and performance characteristics, and intended u...